ArticleJournal of hematology & oncology2013
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.
Article in Journal of hematology & oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.PloS one · 2021Pooled it
- Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.Clinical epigenetics · 2016Pooled it
- Trial
- Article
- Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival.Cancers · 2022Article
- Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?Haematologica · 2021Article
- Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML.Cancer medicine · 2020Article
- American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2020Article
- Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis.Journal of Cancer · 2020Article
- Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern.Blood advances · 2019Article
- Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia.BMC hematology · 2018Article
- Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.International journal of molecular sciences · 2017Article
- Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.Journal of hematology & oncology · 2016Article
- Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.Journal of hematology & oncology · 2015Article
- The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.Journal of hematology & oncology · 2015Article
- An ATRActive future for differentiation therapy in AML.Blood reviews · 2015Article
- Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.American journal of hematology · 2015Article
- Upregulated TCRζ improves cytokine secretion in T cells from patients with AML.Journal of hematology & oncology · 2015Article
- Clinical Results of Hypomethylating Agents in AML Treatment.Journal of clinical medicine · 2014Review
- Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer.Case reports in oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment options in older acute myeloid leukaemia (AML) patients include intensive chemotherapy, best supportive care (BSC), and hypomethylating agents. Currently, limited data is available on hypomethylating agents in older AML patients in unselected patient populations.
methodsTo compare the effectiveness of azacitidine with conventional therapy, we collected data of 227 consecutive AML patients (≥60 years) who were treated with azacitidine (N = 26), intensive chemotherapy (N = 90), or BSC (N = 97).
resultsAzacitidine-treated patients were older and had more comorbidities, but lower white blood cell- and bone marrow blast counts compared with intensive chemotherapy patients. Complete or partial response was achieved in 42% of azacitidine-treated patients and in 73% of intensive chemotherapy patients (P = 0.005). However, the overall survival (OS) was similar (1-year-OS 57% versus 56%, P = 0.93; 2-year-OS 35% versus 35%, P = 0.92), and remained similar after correction for risk factors in a multivariate analysis. Patients treated with BSC had an inferior OS (1-year- and 2-year-OS 16% and 2%, P < 0.001). Compared to intensive chemotherapy, azacitidine-treated patients spent less days in the hospital (median in first three months 0.5 versus 56, P < 0.001), and needed less red blood cell and platelet transfusions (median per month 2.7 versus 7, P < 0.001 and 0.3 versus 5, P < 0.001) in the first three months.
conclusionsAzacitidine treatment is associated with a comparable OS but higher tolerability in a subgroup of older AML patients compared with intensive chemotherapy. Patients receiving BSC had a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.